SCHEMBL2371483

SCHEMBL2371483

COc1cc2c(=O)c3cc(Br)ccc3oc2c(F)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
CSNK2A2 P19784 4/20 0.44
CSNK2B P67870 4/20 0.44
CSNK2A1 P68400 2/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 2/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571194 0.81 NPC1 (0.55) NPC1KMT2AMEN1CSNK2A2CSNK2B
SCHEMBL2372207 0.80 GABRP (0.42) KMT2ACSNK2A2CSNK2BCSNK2A1KDM4E
SCHEMBL2370587 0.79 MAPT (0.54) NPC1KMT2AMEN1CSNK2A2CSNK2B
SCHEMBL570364 0.78 NPC1 (0.55) NPC1KMT2AMEN1CSNK2A2CSNK2B
SCHEMBL19513555 0.77 GABRP (0.42) KMT2ACSNK2A2CSNK2BCSNK2A1KDM4E
SCHEMBL8515753 0.76 MAPT (0.50) NPC1KMT2AMEN1CSNK2A2CSNK2B
SCHEMBL570670 0.73 KDM4E (0.81) NPC1KMT2AMEN1ALDH1A1KDM4E
SCHEMBL2381941 0.73 GPR35 (0.41) CSNK2A2CSNK2BCSNK2A1ALDH1A1MAPT
SCHEMBL29416622 0.73 PIM1 (0.58) NPC1KMT2ACSNK2A2CSNK2BCSNK2A1
SCHEMBL2588529 0.73 PIM1 (0.58) NPC1KMT2ACSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP NPC1 1315/4885KMT2A 3694/4885MEN1 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.